Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H, Horiguchi J, Takata D, Kikuchi M, Rokutanda N, Nagaoka R, Sato A, Odawara H, Tozuka K, Oyama T, Takeyoshi I. Tokiniwa H, et al. Among authors: takeyoshi i. Breast Cancer. 2012 Oct;19(4):309-14. doi: 10.1007/s12282-011-0291-4. Epub 2011 Jul 2. Breast Cancer. 2012. PMID: 21725655
ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S, Inoue K, Takei H, Matsumoto H, Kurosumi M, Horiguchi J, Takeyoshi I, Oyama T. Kurozumi S, et al. Among authors: takeyoshi i. BMC Cancer. 2015 Sep 7;15:622. doi: 10.1186/s12885-015-1641-y. BMC Cancer. 2015. PMID: 26345461 Free PMC article.
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.
Kurozumi S, Padilla M, Kurosumi M, Matsumoto H, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Ranger-Moore J, Allred DC, Dennis E, Nitta H. Kurozumi S, et al. Among authors: takeyoshi i. Breast Cancer Res Treat. 2016 Jul;158(1):99-111. doi: 10.1007/s10549-016-3856-2. Epub 2016 Jun 18. Breast Cancer Res Treat. 2016. PMID: 27318853 Free PMC article.
Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Horiguchi J, Oyama T, Takata D, Rokutanda N, Nagaoka R, Odawara H, Tokiniwa H, Tozuka K, Kikuchi M, Sato A, Takeyoshi I. Horiguchi J, et al. Among authors: takeyoshi i. Anticancer Res. 2011 Sep;31(9):3041-6. Anticancer Res. 2011. PMID: 21868556
318 results